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endemic zones. Solid-organ transplant (SOT) recipients have an
increased risk of VL, but the effect of higher incidence rates on
the frequency of VL in SOT is unknown. VL can occur afterClin Microbiol Infect 2015; 21: 89–95
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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gans, blood products or reactivation of latent infections.
Although more than 100 VL case reports have been described
and reviewed in the literature [1–5], there is a lack of infor-
mation regarding risk factors, the role of immunosuppression
and disease outcome across different types of transplantation.
The recognition and management of VL remains challenging
even in transplant recipients from endemic regions [6–11].
The present study was designed to determine the frequency,
risk factors, clinical characteristics and prognosis of VL in SOT
in two countries, Spain and Brazil, in which leishmaniasis is
endemic, although with different incidences in the general
population.Materials and methodsSetting and study population
This retrospective study was conducted at ten Spanish hospitals
(included in the Spanish Network for Research in Infectious
Diseases [REIPI]) and two centers in Brazil. All patients diag-
nosed with VL from January 1995 to June 2012 and January
1995 to December 2011 at the participating transplant centers
in Spain and Brazil, respectively, were included. The patients
were identiﬁed using transplantation program databases. The
initial identiﬁcation was followed by a detailed medical records
review. The study was approved by the institutional review
board of the IMIBIC (Instituto Maiomônides de Investigación
Biomédica de Córdoba)-Hospital Universitario Reina Soﬁa.
For risk factor analysis, a matched case–control study (1:2
ratio) was performed. The control subjects were matched by
three factors: institution, type of transplantation and time of
follow-up after transplantation. Recipients who underwent
transplantation immediately before and after the index case
patient and who survived at least as long as that patient’s
elapsed time to the diagnosis of VL were eligible to be control
subjects.
Deﬁnitions
A VL diagnosis was established on the basis of clinical mani-
festations combined with the demonstration of parasites using
one of the following methods: microscopy, culture, polymerase
chain reaction (PCR) and positive serology (indirect immuno-
ﬂuorescence 1/80 or direct agglutination test [DAT rK39] or
enzyme immunoassay). The time of event was deﬁned as the
time of VL diagnosis after transplant. Pancytopenia was deﬁned
as haemoglobin <12 g/dL, leukocytes <4000/mm3 and platelets
<150 000/mm3, and severe pancytopenia was established as
haemoglobin <10 g/dL, leukocytes <1000/mm3 and platelets
<100 000/mm3.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectVL was considered cured if a patient remained asymptomatic
for 1 month after the end of treatment. For patients who
survived longer than 1 month, recurrence or relapse was
diagnosed when symptoms, signs or laboratory abnormalities
reappeared at least one month after the end of treatment.
Mortality was considered related to VL when the infection had
not been cured by the time of death.
The following variables were analysed as potential risk fac-
tors: sex, age, diabetes mellitus within the preceding 6 months,
human immunodeﬁciency virus (HIV) serology, previous VL,
prophylaxis with intravenous amphotericin B and cytomega-
lovirus disease or replication within the preceding 6 months.
An immunosuppressive status at the time of the event was
deﬁned as follows: an elevated mean calcineurin inhibitor level
within the preceding 30 days (>15 μg/mL for tacrolimus and
>300 ng/mL for cyclosporin), prior use of everolimus and
sirolimus, history of high-dose prednisone therapy within the
preceding 6 months (20 mg of prednisone for >1 month or
>2 pulses of 1 g of intravenous methylprednisolone),
lymphocyte-depleting antibody treatment within the preceding
12 months and allograft rejection within the preceding 6
months.
Microbiologic studies
Leishmania serology, antigen detection, PCR and culture were
performed at each center using routine tests, according to the
manufacturers’ instructions.
Statistical analysis
To detect differences between groups, the χ2 test (or Fisher’s
exact test, when indicated) was used with continuity correction
for categorical variables, and the Student’s t test was used for
continuous variables. The VL-free survival time was calculated
by Kaplan-Meier curves and compared by the log-rank test.
Univariate and multivariate analyses (binary logistic regression)
were performed to identify potential risk factors. All reported p
values are two-tailed.ResultsEpidemiology
The frequency of VL by country and transplanted organ is
shown in Table 1. Thirty-six VL cases were identiﬁed among 25
139 SOT recipients at 12 participating hospitals, representing
0.1% of all transplant recipients. VL cases appeared in 25 (0.2%)
of 12 895 kidney recipients, four (0.05%) of 8681 liver re-
cipients, six (0.2%) of 2669 heart recipients and one (0.2%) of
894 lung recipients. The frequency of VL was 5.7-fold higher in
Brazil (0.5%) than in Spain (0.1%).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 89–95
TABLE 1. Frequency of VL in solid-organ transplant recipients at ten Spanish and two Brazilian hospitals
Transplant
Total Spain Brazil
RR (95% CI)a, p
Cases per total
transplants % (95% CI)
Cases per total
transplants % (95% CI)
Cases per total
transplants % (95% CI)
Kidney 25/12 895 0.2% (0.2–0.3) 15/11 819 0.1% (0.1–0.2) 10/1076 0.9% (0.5–1.6) 7.4 (3.1–17.4), <0.001
Liver 4/8681 0.05% (0.01–0.1) 1/7360 0.01% (0.0–0.1) 3/1321 0.2% (0.1–0.6) 16.1 (1.57–99.9), 0.01
Heart 6/2669 0.2% (0.1–0.5) 5/2535 0.2% (0.1–0.4) 1/134 0.7 (0.04–3.6) 0.3 (0.03–6.0), 0.27
Lung 1/894 0.1% (0.00–0.5) 1/877 0.1% (0.0–0.6) 0/17 — —
All 36/25 139 0.1% (0.1–0.2) 22/22 591 0.1% (0.1–0.2) 14/2548 0.5% (0.3–0.9) 5.7 (2.7–11.6), <0.001
VL, visceral leishmaniasis; RR, relative risk; CI, conﬁdence interval.
aComparison of frequencies in Spain and Brazil.
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was 11 months (range 2–150 months), 7 months in Brazil and
17 months in Spain. Twelve (33.3%) of the 36 patients were
diagnosed with VL within the ﬁrst 6 months after
transplantation.
Risk factors for VL
Risk factors were analysed for the 36 case patients and 72
control subjects (Table 2). No patients or control subject
received prophylaxis with amphotericin B. Treatment in the
preceding 6 months with high-dose prednisone to prevent
organ rejection was the only factor signiﬁcantly associated with
VL (Table 3).
Clinical characteristics of VL
Table 4 presents the clinical characteristics of the 36 SOT pa-
tients with VL. The average follow-up was 51 months. Thirty-
one patients (86%) were febrile at the time of diagnosis. Vis-
ceromegaly (splenomegaly plus hepatomegaly) was observed in
~81% of patients, and adenomegaly was observed in two pa-
tients (5.6%). Pancytopenia was observed in 17 patients (47%),
but none had severe pancytopenia. Three patients exhibited
septic shock at the time of presentation. Thirteen VL patients
(36.1%) had concomitant infections.
Diagnosis
The diagnosis was based on the clinical manifestations of VL and
evidence of the parasite by microscopy (n = 29), cultureTABLE 2. Univariate analysis of risk factors for VL in SOT recipien
Variable Patients (n [
Male sex 27 (75.0)
Age, years, median (range) 46 (14–76)
Diabetes mellitus 7 (19.4)
CMV disease within preceding 6 months 5 (13.9)
CMV replication within preceding 6 months 7 (19.4)
Receipt of lymphocyte-depleting antibody within preceding 12 months 5 (13.9)
Use of cyclosporin vs. tacrolimus 31 (86.1)
Use of mycophenolate 21 (58.3)
Receipt of high-dose steroids within preceding 6 monthsa 15 (41.7)
VL, visceral leishmaniasis; SOT, solid-organ transplant; OR, odds ratio; CI, conﬁdence interv
aHigh-dose prednisone was deﬁned as >20 mg of prednisone for >1 month or >2 pulses of
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiolo(n = 11) or PCR (n = 3) in 32 patients (88.9%). The VL diagnosis
was established solely on the basis of positive serology in four
patients (13.8%, 4/29). Leishmania amastigotes were observed in
the peripheral blood in three of the four patients in whom this
test was performed. Serology was positive in 22 (75.9%) of 29
patients: DAT rK39 in seven, indirect immunoﬂuorescence in
11, enzyme immunoassay in two and urinary antigen in one.
The method for diagnosis was not recorded in one case
(Table 5).
Treatment and outcomes
N-methyl-glucamine (30 mg/kg per day for 20 days) was
administered to nine patients (26%), although the treatment
was changed to liposomal amphotericin B (LamB) in four cases
because of intolerance. One patient was prescribed miltefosine
and was cured after 28 days of treatment. This patient expe-
rienced recurrence 2 months after treatment and was suc-
cessfully treated again with the same protocol. Amphotericin B,
regardless of the formulation, was the most widely used
treatment drug (n = 30/36); it was prescribed as a ﬁrst, second
or combined treatment option. LamB was well tolerated, and in
no instance was treatment stopped because of adverse effects.
The median duration of LamB treatment was 10 days (Table 6).
One patient died on the third day of treatment. Among the
patients who lived longer than 1 month (n = 35), two patients
presented recrudescence of symptoms soon after treatment
and were deﬁned as not cured. Thirty-three patients (94.2%)
were considered to be cured at the 1-month follow-up.ts
36), n (%) Control subjects (n [ 72), n (%) OR (95% CI) p
54 (75.0) 1.0 (0.4–2.5) 1.00
45 (10–76) 0.8 (0.4–1.9) 0.50
18 (25.0) 1.4 (0.5–3.7) 0.52
5 (6.9) 0.5 (0.1–1.7) 0.30
6 (8.3) 0.4 (0.1–1.2) 0.12
7 (9.7) 0.7 (0.2–2.3) 0.53
65 (90.3) 1.5 (0.4–5.1) 0.53
42 (58.3) 1.0 (0.4–2.2) 1.00
16 (22.2) 2.5 (1.1–5.9) 0.03
al; CMV, cytomegalovirus.
1 g intravenous methylprednisolone.
gy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 89–95
TABLE 3. Independent risk factors for VL in SOT recipients as
deﬁned by multivariate logistic regression
Predictor Wald’s χ2 p OR 95% CI
Constant 0.032 0.857 1.07 NA
Receipt of high-dose
steroids
within preceding 6
months
4.313 0.038 2.50 1.05–5.94
For logistic regression analysis, we considered variables with p <0.20 (i.e., receipt
of high-dose steroids or CMV replication) or possible contributing factors to the
occurrence of VL according to the literature (e.g., eosinophils, albumin, kidney
transplantation). The use of high-dose steroids within the preceding 6 months was
identiﬁed as the only risk factor for LV and increased the risk of developing the
disease by 2.5-fold.
VL, visceral leishmaniasis; SOT, solid-organ transplant; OR, odds ratio; CI,
conﬁdence interval; NA, not applicable.
TABLE 5. Diagnostic methods in transplant patients with VL
Method Total Positive, n (%)
Microscopy
Bone marrow 36 29 (80.6)
Blood 4 3 (75.0)
PCRa
Bone marrow 4 3 (75.0)
Blood 3 2 (66.7)
Culture
Bone marrow 20 11 (56.0)
Blood 3 1 (33.3)
Serologyb 29 22 (75.9)
VL, visceral leishmaniasis; PCR, polymerase chain reaction.
aA variety of PCR-based methods were used according to the protocol of each
institution.
bIncludes different methods: indirect immunoﬂuorescence, enzyme immunoassay,
DAT rK39 and urinary antigen.
92 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIThe patient who died within the ﬁrst month after treatment
was not included in the analysis of secondary prophylaxis and
relapse. Secondary prophylaxis was provided to 12 patients
(34.3%). As shown in Table 6, different prophylaxis schemes
were used. Relapses occurred in nine (25.7%) of 35 patients.
Relapse was observed in one (8.3%) of the 12 patients receiving
prophylaxis and in eight (34.8%) of the 23 patients not receiving
prophylaxis (p 0.19, Fisher’s exact test).DiscussionTABLE 6. Treatment and outcomes of 36 SOT recipients with
VL
In this series, VL occurred in 0.1% of SOT recipients from
endemic countries at a median time of 11 months afterTABLE 4. Clinical and laboratory characteristics of 36 SOT
recipients with VL
Variable Patients, no. (%)
Male sex 27 (75.0)
Age, median years (range) 46 (14–76)
Time from transplant to diagnosis, median
months (range)
9 (1–150)
Follow-up, median months (range) 51 (2–237)
Previous symptomatic VL infection 0
Positive HIV serology 0
Amphotericin use 0
Main signs and symptoms
Temperature >38°C 31 (86.1)
Visceromegaly 29 (80.6)
Pancytopenia 17 (47.2)
Coexisting infections 13 (36.1)
Bacterial 8 (22.2)
CMV 5 (13.9)
Tuberculosis 1 (2.8)
Inﬂuenza A H1N1 1 (2.8)
Severe disease
Intensive care unit admission 11 (30.6)
Shock at presentation 3 (8.3)
Laboratory abnormalities at presentation
Albumin, g/dL 3.1 (1.6–4.4)
Serum creatinine, mg/dL 3.9 (0.5–11)
Haemoglobin, g/dL 11.2 (7.5–15.0)
Platelet count, cells/μL 99 900 (18 500–300 000)
Leukocyte count, cells/μL 3320 (1000–14 000)
Neutrophils, cells/μL 2160 (170–7840)
Eosinophils, cells/μL 181 (0–1120)
Note: Data are presented as no. (%) of patients, unless otherwise indicated. CMV,
cytomegalovirus; SOT, Solid Organ Transplant; VL Visceral Leishmaniasis.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infecttransplantation and was associated with high-dose prednisone.
Disease presentation can be atypical; and only one-third of the
patients exhibited the triad of fever, visceromegaly and cyto-
penia. Concomitant infection was not infrequent: ~36% of pa-
tients presented primarily bacterial or cytomegalovirus
infections. LamB was the most widely used treatment, and
relapse was common, observed in about a quarter of the pa-
tients (~25.7%).
This study presents limitations that are inherent to retro-
spective multicenter studies, and the quality of data dependedDrug chosen as ﬁrst treatment (n = 36)
Amphotericin B deoxycholate 4 (11.1)
Liposomal amphotericin B 22 (61.1)
Pentavalent antimonials 9 (25.0)
Miltefosine 1 (2.8)
All treatment regimens a (n = 36)
Amphotericin B 30 (83.3)
Pentavalent antimonials 9 (25.0)
Others 2 (5.5)
Days of treatment, median (range) 10 (3 – 34)
Cure within the ﬁrst month of treatment b 33/35 (94.2)
Secondary prophylaxis after cure (drug option) 12/35
Amphotericin B 9 (25.7)
Others 3 (8.6)
Scheme of secondary prophylaxis (n = 35)
Daily to every other week 9 (25.7)
Monthly 3 (8.6)
Disease after cure (recurrence) * (n = 35)
With prophylaxis 1/12 (8.3)
Without prophylaxis 8/23 (34.8)
Number of episodes/patient (n = 9)
1 4 (44.4)
2 2 (22.2)
3 2 (22.2)
4 1 (11.1)
Time from the end of treatment to relapse (n = 9)
6 months 4 (44.4)
6-12 months 3 (33.3)
>12 months 2 (22.2)
Relapse treatment (n = 9)
Liposomal amphotericin B 7 (77.7)
Pentavalent antimonials 1 (11.1)
Miltefosine 1 (11.1)
Crude mortality at 30 days 1/36 (2.8)
Note: Data are presented as n. (%) of patients or median (range); SOT, Solid
Organ Transplant; VL, Visceral Leishmaniasis; CMV, cytomegalovirus; a treatment
option included ﬁrst, sequential or combined treatment; b number of patients who
survived more than 1 month after treatment (n=35); * p value = 0.19
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 89–95
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long period of time (16 years), with the possible consequences
of missed VL cases and nonstandardized management across
different hospitals. Also, during the time of recruitment, there
was an improvement in diagnostic techniques and an increase in
the availability of treatment options. The number of cases was
nonetheless small (n = 36), despite the considerable number of
SOT recipients assessed (n = 25 139). Nevertheless, we should
also take into account that VL is a rare disease among transplant
recipients, even in endemic regions [1].
In SOT recipients, VL frequency varies according to both the
prevalence of VL in the general population and the organ
transplant type [1]. In Brazil, which is a highly endemic country
(1.8 cases per 100 000 inhabitants), VL among SOT recipients
was 5.7-fold more frequent than in Spain (0.4 cases per 100 000
inhabitants). It is worth mentioning that the incidence of VL in
Brazil ranges from low to high and from no transmission to
intense transmission, depending on location [11]. The fre-
quency of disease among SOT recipients from endemic zones
may also depend on the socioeconomic level of the population,
and in nonendemic countries, VL should be considered in im-
migrants arriving from endemic zones [12,13]. In this study,
neither the socioeconomic category nor the degree of expo-
sure of the recipient was evaluated. No patient was diagnosed
with symptomatic leishmaniasis before transplantation, and
patients were not routinely screened for VL infection. Donor-
derived transmission was not investigated by any method, and
donor origin was not evaluated.
Leishmaniasis is predominantly described in renal transplant
recipients, which is probably related to the preeminence of
kidney transplants as opposed to other types of organ trans-
plants [1,4,14]. Nevertheless, it has been suggested that renal
insufﬁciency and haemodialysis may be factors that contribute
to increased risk [15,16]. Our study cannot provide clear evi-
dence of an association between the type of transplant and risk.
The use of high doses of steroids was identiﬁed as the sole
risk factor for VL. Prior reports demonstrated that steroid use
is related to the development of intracellular infections [17]. In
our study, VL was not related to induction therapy with anti-
lymphocyte globulins or to baseline immunosuppression.
In the transplant scenario, VL is difﬁcult to recognize even in
endemic countries, where delayed diagnosis still occurs.
Although most cases appear within the ﬁrst year after trans-
plantation, VL can develop at any time. In our series, disease
developed more rapidly in Brazil than in Spain, possibly
correlating with Brazil’s higher incidence. Overall, ~20% of VL
cases (n = 6) were diagnosed within the ﬁrst 3 months after
transplantation, and two cases were diagnosed within the ﬁrst
30 days. A recent report suggested that during early disease
onset, transmission is related to the reactivation of a dormantClinical Microbiology and Infection © 2014 European Society of Clinical Microbioloinfection, when immunosuppression is at its highest level [18].
Despite this risk, VL screening is not routinely performed
because the value of serologic and molecular screening of
asymptomatic donors and recipients remains unclear [19,20].
In our series, 14% of patients were afebrile, 19% did not
exhibit visceromegaly and 53% had no pancytopenia. Overall,
only one-third of the patients (n = 12) presented this classic
triad when the diagnosis was established. Considering the high
frequency of atypical VL in SOT [9,18,21–24], disease should
not be ruled out even in the absence of typical signs, particularly
when the recipient or donor has traveled from an endemic
zone.
The most widely used diagnostic method was bone marrow
aspiration microscopy, which had a sensitivity of 80.6%,
consistent with previous studies [1]. Peripheral blood micro-
scopy was positive in three of four cases. Further investigation is
necessary to evaluate whether this high sensitivity occurs in
transplanted patient as described in HIV [4,25,26]. Microscopy
combined with PCR and culture diagnosed VL in up to 89% of
cases. In this series, Leishmania serology was the sole diagnostic
method in four patients. It should be noted that serology is
minimally invasive and could be routinely used for VL diagnosis
in SOT recipients [1,4,20]; however, serology cannot distin-
guish between prior exposure and active infection and may
presents a cross-reaction with other protozoa [20]. Addition-
ally, serologic methods can exhibit a lack of agreement.
Furthermore, the sensitivity is variable, and speciﬁcity can be
unsatisfactory [4,12,19]. however, serology cannot distinguish
between prior exposure and active infection and may presents a
cross-reaction with other protozoa [20]. At the present time,
the best approach for diagnosis remains the combination of
methods [4].
Amphotericin was the drug of choice for the majority of
patients, and the liposomal formulation was preferred [27,28].
Only one patient was treated with miltefosine, which is a new
oral drug [29], but the patient required two treatment courses.
Although our study was not designed to determine the efﬁcacy
and safety of a particular therapy, 10 patients switched from
amphotericin B deoxycholate (n = 4) or N-methyl-glucamine
therapy (n = 6) to LamB, possibly indicating a low tolerance in
the context of SOT. Conversely, LamB was a safe and widely
used drug.
Nine patients experienced recurrence within the ﬁrst year.
Therefore, close monitoring of patients could be especially
useful during the ﬁrst year after treatment. However, it is not
possible to deﬁnitively differentiate relapse from reinfection.
There is no consensus regarding the most effective drug or
whether secondary prophylaxis is beneﬁcial, as demonstrated
for HIV [4,20,30]. Our study was also not designed to examine
the efﬁcacy of secondary prophylaxis, although this strategy cangy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 89–95
94 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIreduce the number of relapses, as suggested in other studies
[20]. Such an analysis would require additional cases or a
prospective design.
In HIV patients, performing PCR on blood samples is
considered a useful tool to monitor therapy and to identify
relapses in treated patients to avoid invasive procedures [4],
and it may be recommended to monitor response in high-risk
patients with immunosuppression, in particular quantitative
PCR. However, no clear information is available on the use of a
positive PCR result to predict relapses in the transplant setting.
The mortality rate was lower than that described in previous
studies [1], likely as a result of accumulated experience.
Despite the limitations, this study presents the largest series
of cases of VL in SOT, allowing us to draw the following con-
clusions regarding the frequency of VL in SOT recipients from
endemic zones: (a) endemicity may be related to early onset of
the disease; (b) the disease can be atypical, thereby delaying the
diagnosis; (c) the risk of VL increases with the use of high-dose
steroids; (d) a combination of diagnostic methods may serve as
the best approach; (e) LamB is the drug of choice and is typically
well tolerated; and (f) in our view, secondary prophylaxis is
recommended to prevent relapse, but this issue remains
unresolved.Transparency declarationSupported by Plan Nacional de I+D+i 2008–2011 and Instituto
de Salud Carlos III, Subdirección General de Redes y Centros
de Investigación Cooperativa, Ministerio de Economía y Com-
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